When will Oura officially announce an IPO?
Short Answer
The model assigns meaningfully higher odds (100.0% model vs 0.0% market) for Oura Health officially announcing an IPO "Before Jul 1, 2026". This is driven by Oura Health's official announcement of its confidential S-1 filing for a proposed IPO on May 21, 2026, indicating the event has already occurred.
1. Executive Verdict
- Since last update (~98d): Headline model probability surged by +94.6pp to 100.0%, with edge flipping, indicating certainty.
- All remaining outcomes saw model probability rise to 100.0% (e.g., +94.0pp), edge flipped, model-led.
- The "Before Apr 1, 2026" outcome was removed, while market probability gained only +12.0pp.
- Confidence score increased significantly by +2.0pp, now at 9.0.
- Oura announced its confidential S-1 filing for IPO on May 21, 2026.
- The event has already occurred for all listed market thresholds.
Who Wins and Why
| Outcome | Market | Model | Why |
|---|---|---|---|
| Before Oct 1, 2026 | 20.0% | 100.0% | Oura Health announced its S-1 filing on May 21, 2026, meaning the event has already occurred. |
| Before Jan 1, 2027 | 67.0% | 100.0% | Oura Health announced its S-1 filing on May 21, 2026, meaning the event has already occurred. |
| Before Apr 1, 2027 | 73.0% | 100.0% | Oura Health announced its S-1 filing on May 21, 2026, meaning the event has already occurred. |
| Before Jul 1, 2027 | 78.0% | 100.0% | Oura Health announced its S-1 filing on May 21, 2026, meaning the event has already occurred. |
| Before Oct 1, 2027 | 85.0% | 100.0% | Oura Health announced its S-1 filing on May 21, 2026, meaning the event has already occurred. |
Current Context
Oura confidentially filed for an IPO, targeting a 2026 listing. Oura Inc., formerly Oura Health, announced on May 21, 2026, that it confidentially submitted a draft registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) for a proposed initial public offering [^][^][^]. The company has not specified an exact IPO date; the process is contingent on SEC review, prevailing market conditions, and other factors. However, reports indicate Oura targets a listing later in 2026 [^][^][^].
Oura reached an $11 billion valuation before its IPO filing. The company was most recently valued at $11 billion in October 2025, following a $900 million Series E funding round led by Fidelity Management & Research Company [^][^][^]. Investment banks reportedly working on the deal include Goldman Sachs, Morgan Stanley, JPMorgan Chase, Allen & Co., and Jefferies [^][^][^].
2. Market Behavior & Price Dynamics
Historical Price (Probability)
Outcome probability
Date
The market for Oura's IPO announcement has traded in a tight, sideways range between 20% and 25% since its inception. Pricing opened at 25% following the company's May 21 announcement that it had confidentially submitted a draft registration statement. The subsequent drift to 20% suggests that initial optimism has moderated as traders weigh the standard contingencies associated with the IPO process, such as the SEC review and prevailing market conditions, which were noted in company statements.
Volume has been exceptionally low, with only 94 contracts traded in total. This thin liquidity indicates a lack of broad participation and suggests the current price reflects weak conviction. The price action has established clear technical levels, with resistance at the 25% opening price and firm support at the 20% level.
Overall, the chart indicates that market sentiment is stable but cautious. Participants are pricing a low, roughly one-in-five chance of an official IPO announcement within the contract's term. While the confidential filing is a known catalyst, the lack of upward price momentum and minimal trading volume show the market remains skeptical about the near-term timing of a public offering.
3. Market Data
Contract Snapshot
For each contract, a YES resolution occurs if Oura officially announces an IPO before the specific date indicated, such as January 1, 2027, April 1, 2027, or July 1, 2027. A NO resolution occurs if Oura does not make an official IPO announcement by that respective date. The market also specifies a maximum payout date of December 31, 2027.
Available Contracts
Market options and current pricing
| Outcome bucket | Yes (price) | No (price) | Last trade probability |
|---|---|---|---|
| Before Oct 1, 2026 | $0.20 | $0.84 | 20% |
| Before Jan 1, 2027 | $0.67 | $0.34 | 67% |
| Before Apr 1, 2027 | $0.73 | $0.33 | 73% |
| Before Jul 1, 2027 | $0.82 | $0.24 | 78% |
| Before Oct 1, 2027 | $0.89 | $0.18 | 85% |
| Before Jan 1, 2028 | $0.94 | $0.11 | 88% |
Market Discussion
Oura announced on May 21, 2026, the confidential submission of its draft S-1 registration statement for an initial public offering (IPO) with the U.S. Securities and Exchange Commission (SEC) [^][^][^]. As of August 2026, Oura has not provided a specific date for its public listing, which is expected to occur after the SEC's review and subject to market conditions [^][^][^]. The timing and market valuation of Oura's IPO are currently active topics on prediction markets, reflecting ongoing investor speculation [^][^].
4. What specific market conditions or SEC review milestones could shift Oura's IPO from its targeted late 2026 window into 2027?
| S-1 Draft Submission Date | May 21, 2026 [^][^][^][^][^] |
|---|---|
| Targeted IPO Window | Late 2026, potentially shifting to 2027 [^][^][^][^][^] |
| Prediction Market Tracking Dates | Before October 1, 2026, or January 1, 2027 [^][^][^][^] |
Oura confidentially filed for an IPO, targeting late 2026. The smart ring manufacturer submitted a draft registration statement (Form S-1) to the SEC on May 21, 2026, for a potential initial public offering [^][^][^][^][^]. While market expectations initially pointed to an IPO in late 2026, the company has indicated that the precise timing remains dependent on prevailing market conditions and the thorough completion of the SEC's review process [^][^][^].
Market conditions and SEC review could delay the IPO. A shift in Oura's IPO timeline into 2027 could result from broader market volatility or changes in investor enthusiasm for the consumer technology and wearable device sectors [^][^][^]. Additionally, if the SEC issues requests for revisions or requires further disclosures during its confidential comment period, the review process could be extended, thereby pushing the IPO timeframe into the subsequent year [^][^][^]. Currently, various prediction markets are monitoring whether Oura will announce its IPO before specific dates, such as October 1, 2026, or January 1, 2027 [^][^][^][^].
5. How does Oura's latest $11 billion valuation compare to the public market multiples of established wearables companies like Garmin and Google (Fitbit) in 2026?
| Oura Health Valuation | $11 billion (October 2025) [^] |
|---|---|
| Oura Health Implied P/S Multiple | roughly 5.5x (based on nearly $2 billion annual revenue for 2026) [^] |
| Garmin Market Capitalization | approximately $49 billion to $57 billion (July 2026) [^][^][^] |
Oura Health's recent valuation implies a P/S multiple of approximately 5.5x. Oura Health achieved an $11 billion valuation in October 2025 [^]. This valuation, when considered against its targeted nearly $2 billion annual revenue for 2026, suggests an implied price-to-sales (P/S) multiple of approximately 5.5x [^][^][^][^][^][^][^]. This multiple is reported to be significantly lower than the valuation multiples typically observed during the peak of the private tech funding boom [^][^][^][^].
Direct public market comparisons with established wearables are challenging due to data limitations. As of July 2026, Garmin's market capitalization ranged from approximately $49 billion to $57 billion, with variations depending on the source and daily market fluctuations [^][^][^]. However, the provided research does not contain sufficient information to establish a public market price-to-sales multiple for Garmin that allows for a direct comparison with Oura's implied P/S multiple. Fitbit is not a separately traded public company in 2026, having been acquired by Google (Alphabet) in early 2021 [^], meaning a direct public market multiple for Fitbit is unavailable for comparison [^]. The research does not specify public market multiples for established wearables like Garmin in a manner that facilitates a direct comparison with Oura's implied P/S multiple.
6. How does Oura's pre-IPO financial profile compare to that of WHOOP in the period leading up to their respective public offerings?
| Oura IPO Filing Status | Confidential draft Form S-1 submitted May 21, 2026 (targeting IPO later in 2026) [^][^][^] |
|---|---|
| Oura 2025 Revenue | Approximately $1 billion [^][^][^] |
| WHOOP Latest Valuation | $10.1 billion (March 2026) [^][^][^] |
Oura actively pursues an IPO, while WHOOP prepares for a future offering. Oura Health Oy has initiated steps towards a potential public offering, having submitted a confidential draft Form S-1 registration statement to the SEC on May 21, 2026, with an IPO anticipated later in the same year [^][^][^]. Conversely, WHOOP currently operates as a private entity, though its CEO, Will Ahmed, has stated that the company is preparing for a future public offering [^].
Both companies demonstrate strong valuations and revenue leading up to potential IPOs. Oura's pre-IPO financial standing includes an $11 billion valuation from a Series E funding round in October 2025, coupled with reported 2025 revenue of approximately $1 billion [^][^][^]. Similarly, WHOOP's most recent private valuation, achieved in a March 2026 Series G round, was $10.1 billion, and the company reported a bookings run rate of $1.1 billion at the end of 2025 [^][^][^].
7. What are the key financial metrics and risk factors disclosed in Oura's S-1 filing, based on typical disclosures for consumer electronics firms?
| S-1 Filing Public Availability | Not publicly available as of August 4, 2026 [^][^][^][^] |
|---|---|
| Confidential S-1 Submission Date | May 21, 2026 [^][^][^][^] |
| Public IPO Date | Not confirmed [^][^] |
Oura confidentially filed its S-1, but a public IPO date is unconfirmed. On May 21, 2026, Oura Health Oy confidentially submitted a draft registration statement on Form S-1 for a proposed initial public offering (IPO) to the U.S. Securities and Exchange Commission (SEC) [^][^][^][^]. The public version of this S-1 filing, however, has not been released as of August 4, 2026 [^][^][^][^]. Furthermore, beyond this confidential submission, no official public IPO date has been confirmed for the company [^][^].
8. What does the recent IPO timing and performance record of lead underwriters Goldman Sachs and Morgan Stanley suggest for Oura's 2026-2027 launch strategy?
| IPO Confidential Filing Date | May 21, 2026 [^] |
|---|---|
| Predicted IPO Announcement | Before October 1, 2026 [^] |
| Morgan Stanley Quarterly IPO Flow | Almost half of $150 billion [^] |
Oura's upcoming IPO faces a competitive market led by top underwriters. Oura's initial public offering, expected in 2026-2027, is being managed by lead underwriters Goldman Sachs and Morgan Stanley within a highly competitive and active market. The success of Oura's deal will be sensitive to broader market sentiment and the performance of previous mega-IPOs [^][^][^]. Oura confidentially submitted IPO paperwork on May 21, 2026 [^][^][^][^][^]. Prediction markets anticipate an official IPO announcement before October 1, 2026 [^][^][^][^][^].
Lead underwriters Goldman Sachs and Morgan Stanley dominate a booming IPO market. These firms are prominent underwriters in the 2026 IPO landscape, handling significant deals such as the SpaceX offering [^][^]. Morgan Stanley, for instance, accounts for nearly half of the $150 billion in quarterly IPO flows, underscoring the high volume of market activity [^]. This significant involvement means Oura's launch strategy must closely align with prevailing market conditions and the outcomes of other major IPOs, given their increasing impact on deal success when managed by these leading underwriters [^][^].
9. What Could Change the Odds
Key Catalysts
Oura Health announced on May 21, 2026, the confidential submission of a draft registration statement (Form S-1) for a proposed Initial Public Offering (IPO) with the SEC [^] [^] [^] . As of August 2026, Oura has not provided a specific IPO date. The company stated the offering would occur after the SEC's review process concludes, subject to prevailing market conditions and other factors [^][^].
Oura is reportedly collaborating with investment banks including Goldman Sachs, Morgan Stanley, JPMorgan Chase, Allen & Co., and Jefferies [^] [^] . The company aims to list later in 2026, contingent on market conditions and the performance of other significant IPOs [^][^]. Oura was valued at $11 billion in October 2025 following a $900 million Series E round and projects approximately $2 billion in revenue for 2026 [^][^][^].
Key Dates & Catalysts
- Expiration: July 08, 2026
- Closes: January 01, 2028
10. Decision-Flipping Events
- Trigger: Oura Health announced on May 21, 2026, the confidential submission of a draft registration statement (Form S-1) for a proposed Initial Public Offering (IPO) with the SEC [^] [^] [^] .
- Trigger: As of August 2026, Oura has not provided a specific IPO date.
- Trigger: The company stated the offering would occur after the SEC's review process concludes, subject to prevailing market conditions and other factors [^] [^] .
- Trigger: Oura is reportedly collaborating with investment banks including Goldman Sachs, Morgan Stanley, JPMorgan Chase, Allen & Co., and Jefferies [^] [^] .
12. Historical Resolutions
Historical Resolutions: 1 markets in this series
Outcomes: 0 resolved YES, 1 resolved NO
Recent resolutions:
- KXIPOOURA-26JUL01: NO (Jul 01, 2026)
